IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company, announced the enrollment of the first patient in its ongoing Phase 1/2 combination trial of IDE397, a potential first-in-class MAT2A inhibitor, with Trodelvy® (sacituzumab govitecan-hziy) for patients with MTAP-deletion non-small cell lung cancer (NSCLC). The study builds on a clinical collaboration and supply agreement with Gilead Sciences and expands the trial beyond MTAP-deletion urothelial cancer.
Science Significance
The trial evaluates a novel combination of IDE397 and Trodelvy targeting MTAP-deletion solid tumors, leveraging synthetic lethality and antibody-drug conjugate (ADC) strategies. IDE397 inhibits MAT2A, a key metabolic enzyme, potentially disrupting tumor growth, while Trodelvy delivers cytotoxic payloads to Trop2-expressing cancer cells. This dual-target approach represents a first-in-class precision therapy strategy in a patient population lacking approved targeted options, particularly for MTAP-deleted NSCLC, which affects up to 20% of cases.
Regulatory Significance
The combination therapy is investigational, with IDE397 and Trodelvy not yet approved for MTAP-deletion NSCLC or urothelial cancer. The trial is conducted under standard clinical study protocols and collaboration agreements, ensuring compliance with U.S. FDA regulatory frameworks. IDEAYA retains sponsorship and oversight, while Gilead provides Trodelvy supply, enabling streamlined regulatory oversight for combination trials.
Business Significance
Advertisement
The expansion into NSCLC reflects IDEAYA’s strategic growth in precision oncology and partnership leverage with Gilead. By targeting a molecularly defined patient subset, the trial strengthens IDEAYA’s clinical pipeline and positions the company to advance potentially first-in-class therapies that could transform care for solid tumors with MTAP-deletion. Intellectual property rights for respective compounds remain with IDEAYA and Gilead.
Patients’ Significance
Patients with MTAP-deletion NSCLC currently have limited treatment options. This trial offers access to an innovative combination therapy that may improve outcomes by addressing tumors at a molecular level. The first-patient-in milestone represents a critical step toward potential new therapies for a patient population with significant unmet needs.
Policy Significance
The collaboration underscores the role of clinical study agreements and investigational drug pathways in advancing novel cancer therapies. Such frameworks allow biotech companies to access critical compounds and conduct combination trials efficiently while adhering to regulatory safety standards, expediting the evaluation of innovative treatments in precision medicine.
Transaction Highlights
IDEAYA and Gilead maintain commercial rights to their respective agents. Trodelvy is provided by Gilead for investigational use in this trial, while IDEAYA leads trial sponsorship and operational execution. The trial expansion into MTAP-deletion NSCLC reflects strategic prioritization of high-need oncology populations and strengthens the companies’ collaborative development framework.
Source: IDEAYA Biosciences, Inc. Press Release
